File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Continuous entecavir for treatment naı¨ve chinese chronic hepatitis B patients in the real world setting the seven year results

TitleContinuous entecavir for treatment naı¨ve chinese chronic hepatitis B patients in the real world setting the seven year results
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2015
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 24th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2015), Istanbul, Turkey, 12-15 March 2015. In Hepatology International, 2015, v. 9 suppl. 1, p. S204, abstract no. 1518-S205 How to Cite?
AbstractBACKGROUND: There is paucity of data on uninterrupted entecavir for treatment-naı¨ve chronic hepatitis B (CHB) beyond 6 years. METHODS: Treatment–naı¨ve Chinese CHB patients were treated continuously with entecavir for up to 7 years. The cumulative rates of HBV DNA undetectability, alanine aminotransferase (ALT) normalization, hepatitis B e-antigen (HBeAg) seroconversion, virological breakthrough, hepatitis B surface antigen (HBsAg) reduction and genotypic resistance to entecavir were determined. HBV DNA levels were measured by Roche Taqman real time PCR assay. Resistance profile was determined by line probe assay (LiPA, Innogenetics NV, Gent, Belgium). Serum HBsAg levels were performed using Elecsys HBsAg II assay (Roche Diagnostics, Gmbh, Mannheim). RESULTS: 222 Chinese CHB patients (median age 45 years, 70.7 % male) were recruited. 222, 188, 173, 170, 167,162 and 160 patients were followed up for 1, 2, 3, 4, 5, 6 and 7 years respectively. The cumulative rate of HBV DNA undetectability, ALT normalization, HBeAg seroconversion (90 patients were HBeAg positive at baseline) were 98.7, 98.3, 90.2 % up to year 7 respectively. The cumulative rate of virologic breakthrough was 8.3 %. Entecavir signature mutations were found in 2 patients. The cumulative rate of entecavir resistance up to 7 years was 1.2 %. The median rate of HBsAg reduction over 6 years of treatment was 0.095 log IU/ml/year. 15.2 and 7.9 % patients had HBsAg levels less than 200 and 100 IU/mL at the last follow-up. 2 patients developed HBsAg seroconversion at year 2 and 6 respectively. There were no serious adverse events reported. CONCLUSION: Prolonged,uninterrupted entecavir therapy is an effective and safe treatment for CHB patients.
DescriptionConference Theme: New Horizons from East to west in Hepatology
Topic 11 - Hepatitis B: no. 1518
This journal suppl. entitled: Conference Abstracts: 24th Annual Conference of APASL, March 12-15, 2015, Istanbul, Turkey
Persistent Identifierhttp://hdl.handle.net/10722/214871
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669

 

DC FieldValueLanguage
dc.contributor.authorLam, YF-
dc.contributor.authorSeto, WK-
dc.contributor.authorFung, J-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, MF-
dc.date.accessioned2015-08-21T12:00:28Z-
dc.date.available2015-08-21T12:00:28Z-
dc.date.issued2015-
dc.identifier.citationThe 24th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL 2015), Istanbul, Turkey, 12-15 March 2015. In Hepatology International, 2015, v. 9 suppl. 1, p. S204, abstract no. 1518-S205-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/214871-
dc.descriptionConference Theme: New Horizons from East to west in Hepatology-
dc.descriptionTopic 11 - Hepatitis B: no. 1518-
dc.descriptionThis journal suppl. entitled: Conference Abstracts: 24th Annual Conference of APASL, March 12-15, 2015, Istanbul, Turkey-
dc.description.abstractBACKGROUND: There is paucity of data on uninterrupted entecavir for treatment-naı¨ve chronic hepatitis B (CHB) beyond 6 years. METHODS: Treatment–naı¨ve Chinese CHB patients were treated continuously with entecavir for up to 7 years. The cumulative rates of HBV DNA undetectability, alanine aminotransferase (ALT) normalization, hepatitis B e-antigen (HBeAg) seroconversion, virological breakthrough, hepatitis B surface antigen (HBsAg) reduction and genotypic resistance to entecavir were determined. HBV DNA levels were measured by Roche Taqman real time PCR assay. Resistance profile was determined by line probe assay (LiPA, Innogenetics NV, Gent, Belgium). Serum HBsAg levels were performed using Elecsys HBsAg II assay (Roche Diagnostics, Gmbh, Mannheim). RESULTS: 222 Chinese CHB patients (median age 45 years, 70.7 % male) were recruited. 222, 188, 173, 170, 167,162 and 160 patients were followed up for 1, 2, 3, 4, 5, 6 and 7 years respectively. The cumulative rate of HBV DNA undetectability, ALT normalization, HBeAg seroconversion (90 patients were HBeAg positive at baseline) were 98.7, 98.3, 90.2 % up to year 7 respectively. The cumulative rate of virologic breakthrough was 8.3 %. Entecavir signature mutations were found in 2 patients. The cumulative rate of entecavir resistance up to 7 years was 1.2 %. The median rate of HBsAg reduction over 6 years of treatment was 0.095 log IU/ml/year. 15.2 and 7.9 % patients had HBsAg levels less than 200 and 100 IU/mL at the last follow-up. 2 patients developed HBsAg seroconversion at year 2 and 6 respectively. There were no serious adverse events reported. CONCLUSION: Prolonged,uninterrupted entecavir therapy is an effective and safe treatment for CHB patients.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology International-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/10.1007/s12072-015-9609-1-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleContinuous entecavir for treatment naı¨ve chinese chronic hepatitis B patients in the real world setting the seven year results-
dc.typeConference_Paper-
dc.identifier.emailLam, YF: fyflam@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailFung, J: jfung@hkucc.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityFung, J=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.doi10.1007/s12072-015-9609-1-
dc.identifier.hkuros248060-
dc.identifier.volume9-
dc.identifier.issuesuppl. 1-
dc.identifier.spageS204, abstract no. 1518-
dc.identifier.epageS205-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats